Research Analysts Issue Forecasts for BRTX FY2024 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Stock analysts at Roth Capital lifted their FY2024 earnings estimates for shares of BioRestorative Therapies in a research report issued to clients and investors on Thursday, November 14th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($1.43) for the year, up from their prior estimate of ($1.76). The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at $3.43 EPS.

Separately, Roth Mkm upped their target price on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th.

BioRestorative Therapies Trading Up 2.6 %

BRTX stock opened at $1.39 on Monday. The firm has a 50 day simple moving average of $1.63 and a 200-day simple moving average of $1.60. The company has a market capitalization of $9.62 million, a P/E ratio of -0.86 and a beta of 63.40. BioRestorative Therapies has a twelve month low of $1.03 and a twelve month high of $3.67.

BioRestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.22. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%. The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.30 million.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.